The estimated Net Worth of Partners Ltd Phase4 Venture... is at least 50.5 百万$ dollars as of 30 January 2018. Partners Venture owns over 100,000 units of Albireo Pharma Inc stock worth over 47,039,485$ and over the last 7 years Partners sold ALBO stock worth over 3,444,000$.
Partners has made over 1 trades of the Albireo Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Partners sold 100,000 units of ALBO stock worth 3,444,000$ on 30 January 2018.
The largest trade Partners's ever made was selling 100,000 units of Albireo Pharma Inc stock on 30 January 2018 worth over 3,444,000$. On average, Partners trades about 100,000 units every 0 days since 2018. As of 30 January 2018 Partners still owns at least 1,065,447 units of Albireo Pharma Inc stock.
You can see the complete history of Partners Venture stock trades at the bottom of the page.
Over the last 8 years, insiders at Albireo Pharma Inc have traded over 26,339,822$ worth of Albireo Pharma Inc stock and bought 932,623 units worth 30,497,757$ . The most active insiders traders include Advisors Llcperceptive Life...、Roger Jeffs、Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of 957,260$. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth 4,468$.
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Albireo Pharma Inc executives and other stock owners filed with the SEC include: